
    
      This is a global, phase III, double blind, randomized controlled study to compare the
      efficacy, safety & immunogenicity of LUBT010 with Lucentis® in patients with neovascular
      age-related macular degeneration.

      Eligible patients will be randomly assigned in 1:1 ratio to receive once monthly intravitreal
      injection of LUBT010 or Lucentis® for 12 months.
    
  